Last reviewed · How we verify
NCT04710134
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Phase 4 trial testing Reslizumab in Asthma; Eosinophilic in 10 participants. Completed in 9 January 2024.
9 January 2024
Quick facts
| Lead sponsor | McMaster University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 10 February 2021 |
| Primary completion | 9 January 2024 |
| Estimated completion | 9 January 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Reslizumab (RESLIZUMAB) — full drug profile →
Conditions studied
- Asthma; Eosinophilic — all drugs for Asthma; Eosinophilic →
Sponsor
McMaster University
Who can join
Adults 18 to 75, any sex, with Asthma; Eosinophilic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
Hussain M, Liu G. · · 2024 · cited 60× · PMID 38474348 · DOI 10.3390/cells13050384 -
Anti-IL-5 therapies for asthma.
Farne HA, Wilson A, Milan S, Banchoff E, et al · · 2022 · cited 37× · PMID 35838542 · DOI 10.1002/14651858.cd010834.pub4 -
Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study.
Mukherjee M, Bernaola J, Nolasco S, Kjarsgaard M, et al · · 2025 · cited 4× · PMID 39286951 · DOI 10.1111/all.16322
Verify or expand the search:
- PubMed search for NCT04710134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Reslizumab
Trials testing the same drug.
- NCT04183192 — Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists · Phase 1 · completed
- NCT03369574 — Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab · withdrawn
- NCT02937168 — An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation · Phase 4 · terminated
- NCT03074942 — Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab · Phase 2 · completed
- NCT02501629 — An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevat · Phase 3 · completed
Other recruiting trials for Asthma; Eosinophilic
Currently open trials in the same condition.
- NCT06488755 — SIM0718 Treatment of Asthma Clinical Study · Phase 3 · recruiting
- NCT06288516 — BenRalizumab Effect on Airway Remodeling in Severe asTHma · Phase 4 · recruiting
- NCT05942222 — A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis Wit · Phase 4 · active not recruiting
- NCT05404763 — Mepolizumab and Physical Activity in Severe Asthma · recruiting
- NCT05144087 — The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma · active not recruiting
Other McMaster University trials
Trials by the same sponsor.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
- NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
- NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04710134 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster University
- Last refreshed: 25 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04710134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing